Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Tardive Diaphragmatic Tremor
Neurol 94:e656, Gupta, H.V., 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
The Dangers of PRES
Neurol 92:e282-e285, Chaterine, C.,et al, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Serotonin Syndrome Associated with Clozapine Withdrawal
JAMA Neurol 70:1054-1055, Stevenson, E.,et al, 2013
Tumefactive MS Lesions under Fingolimod
Neurol 81:1654-1658, Pilz, G.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008
Exposure to Antipsychotics and Risk of Stroke: Self Controlled Case Series Study
BMJ 337:616-618,586, Douglas,I.J. &Smeeth,L., 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Delirium in Older Persons
NEJM 354:1157-1165, Inouye,S.K., 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Atypical Antipsychotic Drugs and Risk of Ischaemic Stroke: Population Based Retrospective Cohort Study
BMJ 330:445-448, Gill,S.S., et al, 2005
Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances
Dept Health & Human Services (Apr), FDA Public Health Advisory, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Atypical Antipsychotic Drugs in the Treatment of Behavioural and Psychological Symptoms of Dementia: Systematic Review
BMJ 329:75-78, Lee,P.E.,et al, 2004
Ten Most Commonly Asked Questions About the Psychiatric Aspects of Parkinson's Disease
The Neurologist 9:50-56, Reich,S.G. & Marsh,L., 2003
Drug-Induced Pisa Syndrome (Pleurothotomus)
CNS Drugs 10:166-174, Suzuki, T. & Matsuzaka, H., 2002
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
Olanzapine and Clozapine Comparative Effects on Motor Function in Hallucinating PD Patients
Neurol 55:789-794, 748, Goetz,C.F. et al, 2000
Treatment of Drug-Induced Psychosis with Quetiapine and Clozapine in Parkinson's Disease
Neurol 55:1753-1754, Dewey,R.B.Jr. & O'Suilleabhain,P.E., 2000
Psychiatric Emergencies, The Neuroleptic Malignant and Serotonin Syndromes
Emerg Med Clin North Am 18:317-325, Carbone,J.R., 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Neurologic Side Effects in Neuroleptic-Naive Patients Treated with Haloperidol or Risperidone
Neurol 52:782-785, Rosebush,P.I.&Mazurek,M.F., 1999
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Olanzapine:A Novel Atypical Neuroleptic Agent
Lancet 349:1264-1265, Reus,V.I., 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Extrapyramidal Side Effects with Low-Dose Risperidone
Can J Psychiatry 42:325-325, Brown, E.S., 1997
Clozapine-Induced Myotoxicity in Patients with Chronic Psychotic Disorders
Neurol 47:1518-1523, Scelsa,S.N.,et al, 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Low-Dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Neurol 45:432-434, Rabey,J.M.,et al, 1995
Clozapine-Related Seizures:Experience with 5, 629 Patients
Neurol 44:2247-2249, Pacia,S.V.&Devinsky,O., 1994
Risperidone
Lancet 343:457-460, Livingston,M.G., 1994
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992